Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy

Table 3 Clinicopathological Characteristics: Univariate and Multivariate Survival Analyses

Characteristic	DFS
	Univariate		Multivariate
	HR (95%CI)	P	HR (95%CI)	P
Age	1.033 (0.995–1.072)	0.007	1.031 (0.973–1.093)	0.295
Menopause vs no menopause	1.693 (0.672–4.268)	0.257	0.927 (0.227–3.790)	0.916
Stage (III vs II vs I)	4.411 (1.396–13.938)	0.015	3.801 (1.163–12.427)	0.027
Molecular type (HR+ vs Her-2 vs TNBC)	0.926 (0.559–1.534)	0.756	0.916 (0.606–1.384)	0.676
Low TIN after NACT VS High TIN after NACT	3.415 (1.489–7.831)	0.002	3.265 (1.374–7.758)	0.007

Abbreviation: HR Hormone receptor, Her-2 Human epidermal growth factor receptor-2, TNBC Triple negative breast cancer, DFS Disease free survival, TIN Tumor infiltrating neutrophil, NACT Neoadjuvant chemotherapy

ISSN: 1471-2407